WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the Board of Directors has elected Bruce L.A. Carter, Ph.D. as non-executive Chairman of the Board. Dr. Carter has been an independent director of Enanta since November 2013. He currently serves as the Chair of the Compensation Committee and is a member of the Nominating and Corporate Governance Committee.
